Abstract P-006

006 Luetic.p65

( )* +,+ . / -,0,1)*,2 1 * 3 4 5 26 7 (,) ( 5& / 8 ) ,6 ,26 1)* 8 ) 6 9 3 / 8 / (,) , ) 6 9 / ( ,8 )+ * % ,70 6,8 4 / . ( ) 6 ( , ) 8 8 +,4 . 8 +6 3,2 * ( 8)*,2 9 3, :6& 3 )*,/ ( / +,+ . / ( / -,8 3 0 )3,/ ) ( )* ( 7 , ,(,7 * 63 )*,2 (6 5 3 / + * ( / -,8 , +,) *, 0 365 * ) ( / ; 36 / ( ) 6 9 / 0 ) 6 * 6 % 6 ( )8, ) ,26 4 )*-/ 4 3, ) 6 9 3 / ),. / )* ) ( -,0& ,1)*,2 1 * + / )*, 3 0 0 / ,3 ),. / ...

Innovative Medical Technology Overview: Number 006/2016

Granulox ® is a patent-protected first in class medical device. Granulox ® is positioned for use as an add-on therapy to standard care for the treatment of chronic wounds including venous leg ulcers, pressure ulcers and diabetic foot ulcers which have failed to heal after a period of standard care. Beyond administration of the spray, Granulox ® is not expected to impact upon the standard wound ...

OR10-006 - Canakinumab in patients with TRAPS

Introduction TNF-receptor associated periodic syndrome (TRAPS) is a rare, dominantly inherited periodic fever syndrome due to mutations of the TNFRSF1A gene. The IL-1 receptor antagonist anakinra has been reported to be an efficacious daily treatment. Canakinumab (CAN) is a fully human monoclonal selective anti-IL-1b antibody with a T1/2 of ~4 wks. Interim clinical and PK data of CAN treatment ...

abstract

ABSTRACT